Compare Eos Energy Enterprises Inc (EOSE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Novo Nordisk A/S — how do they compare? Eos Energy Enterprises Inc trades at $2.78 (market cap $1.01B), while Novo Nordisk A/S trades at $38.2 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 163.7× Eos Energy Enterprises Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Novo Nordisk A/S for 116 Days on average.
| EOSE | NVO | |
|---|---|---|
Market Cap | $1.01B | $165.31B |
Volume | 39,626,541 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $19.19 | $63.98 |
52-Week Low | $2.77 | $35.29 |
Typical Hold Time | 16 Days | 116 Days |
Enterprise Value | $1.34B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% today, amid a bearish technical signal. The company is in a high-growth phase, with revenue surging from $114 million in 2025 to $214 million in 2026, but it remains deeply unprofitable, with a net income margin of -246.76% in 2026. Recent positive developments include a major partnership with Google for a $350 million West Virginia project and an $87 million Department of Energy loan advance to expand manufacturing capacity.
The outlook is a high-risk, high-reward proposition. Significant revenue growth and strategic partnerships offer substantial upside potential, with a consensus price target of $7.10. However, persistent negative cash flow from operations, high debt-to-asset ratio of 91.87%, and intense competition in the energy storage sector pose severe risks to shareholder value.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
